Kinderhook, N.Y., November 13, 2018 – American Bio Medica Corporation (OTCPK: ABMC) today announced financial results for the three and nine months ended September 30, 2018.

Chief Executive Officer Melissa A. Waterhouse stated, “Although sales declined in the third quarter of 2018 when compared to the third quarter of 2017, we are still expecting new relationships/contracts to positively impact sales going forward into 2019. One of these contracts was just signed in the fourth quarter of 2018. In addition, we are also hopeful that sales in the near future will be positively impacted by our ability to sell oral fluid drug tests in more market segments and by new contract manufacturing accounts.” Waterhouse concluded, “Any sales increases will continue to be accompanied by reasonable operational and manufacturing expenses.”

Financial Highlights

  • Net sales in the third quarter of 2018 were $878,000, compared to $1,354,000 in the third quarter 2018, a decrease of 35.2%. Net sales in the nine months ended September 30, 2018 were $2,988,000, compared to $3,975,000 in the nine months ended September 30, 2017, a decrease of 24.8%.
  • Operating loss was $132,000 in the third quarter of 2018, compared to an operating income of 5,000 in the third quarter of 2017. Operating loss was $413,000 in the nine months ended September 30, 2018, compared to an operating loss of $83,000 in the nine months ended September 30, 2017.
  • Net loss was $202,000 in the third quarter of 2018, compared to net loss of $49,000 in the third quarter of 2017. Net loss was $615,000 in the nine months ended September 30, 2018, compared to net loss of $252,000 in the nine months ended September 30, 2017.

For more information on ABMC or its drug testing products, please visit www.abmc.com.

About American Bio Medica Corporation

American Bio Medica Corporation manufactures and markets accurate, cost-effective immunoassay test kits, primarily point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC’s Rapid Drug Screen®, Rapid ONE®, RDS® InCup®, Rapid TOX® and Rapid TOX Cup® II test for the presence or absence of drugs of abuse in urine, while OralStat® tests for the presence or absence of drugs of abuse in oral fluids. ABMC’s Rapid Reader® is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, risks and uncertainties related to the following: continued acceptance of our products, increased levels of competition in our industry, acceptance of new products, product development, compliance with regulatory requirements, including but not limited to our ability to obtain marketing clearance on our products for our intended markets, intellectual property rights, our dependence on key personnel, third party sales and suppliers, trading in our common shares may be subject to “penny stock” rules, our history of recurring net losses and our ability to continue as a going concern. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled “Risk Factors” in the Company’s annual report on Form 10-K for the year ended December 31, 2017, quarterly reports on Form 10-Q, and other periodic reports on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company’s common shares.

AMERICAN BIO MEDICA CORPORATION

Condensed Statements of Operations

 

(unaudited)

 

 

For the three

 

For the three

 

 

months ended

 

months ended

 

 

March 31, 2018

 

March 31, 2017

 

 

 

 

 

Net sales

$

1,041,000

$

1,316,000

Cost of goods sold

 

669,000

 

751,000

       Gross profit

 

372,000

 

565,000

 

 

 

 

 

Operating expenses:

 

 

 

 

  Research and development

 

25,000

 

46,000

  Selling and marketing

 

161,000

 

196,000

  General and administrative

 

392,000

 

390,000

       Total operating expenses

 

578,000

 

632,000

 

 

 

 

 

Operating loss

 

(206,000)

 

(67,000)

 

 

 

 

 

Other expense

 

(61,000)

 

(65,000)

 

 

 

 

 

Net loss before tax

 

(267,000)

 

(132,000)

 

 

 

 

 

Income tax expense

 

0

 

0

 

 

 

 

 

Net loss

$

(267,000)

$

(132,000)

 

 

 

 

 

Basic & diluted (loss) / income per
common share

$

(0.01)

$

(0.00)

 

 

 

 

 

Weighted average shares outstanding –
basic

 

29,882,770

 

28,842,788

Weighted average shares outstanding –
diluted

 

29,822,770

 

28,842,788

 

(Condensed
Balance Sheets follow)

 

 

American Bio Medica Corporation

Condensed Balance Sheets

 

 

March 31,

 

December 31,

 

 

2018

(unaudited)

 

2017

 

ASSETS

 

 

 

 

Current Assets

 

 

 

 

Cash and
cash equivalents

$

92,000

$

36,000

Accounts
receivable, net of allowance for doubtful accounts of $51,000 at March 31,
2018 and $52,000 at December 31, 2017

 

 

421,000

 

 

348,000

Inventory,
net of allowance of $521,000 at March 31, 2018 and $500,000 at December 31,
2017

 

 

1,388,000

 

 

1,473,000

Prepaid
expenses and other current assets

 

61,000

 

97,000

Total current assets

 

1,962,000

 

1,954,000

Property, plant and equipment, net

 

774,000

 

792,000

Patents, net

 

113,000

 

109,000

Other assets

 

21,000

 

21,000

Deferred finance costs – line of credit,
net

 

7,000

 

15,000

Total assets

$

2,877,000

$

2,891,000

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

Current liabilities

 

 

 

 

Accounts
payable

  $

430,000

$

374,000

Accrued
expenses and other current liabilities

 

354,000

 

311,000

Wages
payable

 

266,000

 

259,000

Line of
credit

 

492,000

 

446,000

Current
portion of long
term debt

 

237,000

         

87,000

Total current liabilities

 

1,779,000

 

1,477,000

Other liabilities/debt

 

16,000

 

19,000

Long-term debt, net of current portion and deferred
finance costs

 

704,000

 

772,000

Total liabilities

 

2,499,000

 

2,268,000

COMMITMENTS AND CONTINGENCIES

 

 

 

 

Stockholders’ Equity:

 

 

 

 

Common
stock

 

299,000

 

298,000

Additional
paid-in capital

 

21,191,000

 

21,170,000

Accumulated
deficit

 

(21,112,000)

 

(20,845,000)

Total stockholders’ equity

 

378,000

 

623,000

Total liabilities and stockholders’ equity

$

2,877,000

$

2,891,000

#####